



SERES
THERAPEUTICS™

Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer

June 22, 2020

– Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres' microbiome therapeutic pipeline –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 22, 2020-- [Seres Therapeutics, Inc.](https://www.businesswire.com/news/home/20200622005155/en/) (Nasdaq: MCRB) today announced the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer, effective June 29, 2020. Dr. Young brings to Seres over 20 years of commercial and marketing leadership experience, having successfully led the growth of several important biopharmaceutical products.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20200622005155/en/>



Terri Young, Ph.D., R.Ph. (Photo: Business Wire)

"We are thrilled to welcome Terri to the Seres team ahead of our anticipated, potentially pivotal SER-109 ECOSPOR III Phase 3 study readout in patients with recurrent *C. difficile* infection. Terri's extensive marketing and sales leadership experience will be invaluable as we continue to prepare for the potential commercialization of SER-109," said Eric Shaff, President and Chief

Executive Officer of Seres. "In addition to SER-109, Terri will support the advancement of our overall microbiome therapeutic pipeline targeting infectious diseases, immunological conditions and cancer. In particular, we look forward to Terri's contributions on our promising SER-287 program, which is in a Phase 2b study for ulcerative colitis."

"I am excited to join Seres as the Company prepares for the potential commercialization of SER-109. Recurrent *C. difficile* is a condition where improved treatment options are urgently needed, and SER-109 has the potential to fundamentally transform how patients are managed," said Dr. Young. "In addition to SER-109, Seres is advancing an innovative pipeline of microbiome therapeutic candidates, including SER-287 and SER-301 for ulcerative colitis and SER-401 and SER-155 for cancer. I look forward to working with the team to implement strategies that maximize the enormous potential of this novel therapeutic modality."

Prior to joining Seres, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics, where she led development of Sage's global commercial capabilities, including global marketing, insights and analytics and new product planning. Previously, she held commercial leadership roles of increasing responsibility at Bristol-Myers Squibb, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS® business to become the company's largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline, where she catalyzed growth for the company's Urology, Diabetes and NeuroHealth organizations. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina. Dr. Young is a member of the Women in Bio and Healthcare Businesswomen's Association, and served on the Advisory Board of the Healthcare Businesswomen's Association.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent *C. difficile* infection. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing and results of each of Seres' clinical studies, Seres' commercialization plans, the promise and potential impact of microbiome therapeutics and other statements that are not historical facts.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: We have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the ability to develop and commercialize our product candidates, if approved; the potential impact of the COVID-19 pandemic; our ability to retain key personnel and to manage our growth; and that our management and principal stockholders have the ability to control or significantly influence our business. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 7, 2020 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at

some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200622005155/en/): <https://www.businesswire.com/news/home/20200622005155/en/>

PR Contact

Lisa Raffensperger

lisa@tenbridgecommunications.com

IR Contact

Carlo Tanzi, Ph.D.

ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.